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Ciproﬂoxacin, commonly used in India as an anti-microbial for prolonged use in chronic and non-speciﬁc
indications, may affect the bioavailability of the drug. The drug prescribed is commonly taken with
multivitamins, calcium and milk. A simple and reliable analytical methodology obtaining a correlation
with in vivo urinary excretion studies using UV and HPLC and in vitro dissolution studies (IVIVC) has
shown a signiﬁcant increase in elimination rate of ciproﬂoxacin co-administered with multivitamins,
calcium and milk. Appreciable IVIVC results proved that dissolution studies could serve as an alternative
to in vivo bioavailability and also support bio-waivers.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Development of antimicrobial resistance is a challenging pro-
blem in world health scenario, despite the increasing demand for
antimicrobials in global pharmaceutical market worths a current
value of about $66.5 billions [1]. However, antibiotics are one of
the most widely used and frequently misused drugs. Due to wide
predominance of infectious diseases and emergence of resistant
strains, there is an increased inclination among clinicians to prefer
newer-generation antibiotics as one of the ﬁrst-line therapeutic
regimens. However, prolonged antibiotic therapy may give rise to
some side effects like anemia, dyspepsia, hyperacidity, gastritis,
hepatotoxicity and nephrotoxicity, which necessitate co-medica-
tions. Such co-medications include common antacids or multi-
vitamins (MVs) which are either prescribed by physicians or self-
advised and that may adversely affect the bioavailability of the
antibiotic prescribed. Thus, the anti-microbial effect of the drug is
compromised, leading to prolonged consumption of the antibiotic
and development of antimicrobial resistance against that parti-
cular antibiotic [2–4].on and hosting by Elsevier B.V. All
University.
: þ91 32 22279970.
a).Fluoroquinolones administered orally have been a preferred
choice for clinicians in treatment of grave infections for decades.
Ciproﬂoxacin (CPFX) is a ﬂuoroquinolone carboxylic acid deriva-
tive and broad-spectrum antibiotic active against Gram-positive
and Gram-negative organisms. Pharmacokinetically, CPFX under-
goes renal and hepatic bio-degradative pathways. After 24 h of
administration, approximately 50% of oral dosage or 80% of in-
travenous dosage appears in the urine either as parent compounds
or as metabolites. Renal excretion of CPFX is nearly thrice the
glomerular ﬁltration rate, highlighting the role of tubular secretion
and anionic transport mechanism in the elimination of this car-
boxyﬂuoroquinolone. As a popular oral antibiotic with rapid onset
of action, it is used in treatment of numerous infectious diseases
afﬂicting the skin, bones, gastrointestinal tract (GI-tract), geni-
tourinary tract, and meninges. Mechanistically, CPFX acts by ef-
fective inhibition of DNA gyrase preventing DNA replication in
susceptible bacteria [5]. Patients under prolonged CPFX therapy
are reported to suffer from hyperacidity, nausea, vomiting, gas-
tritis, pain in the abdomen, and anemia and hence they consume
antacids often without medical supervision. Calcium or magne-
sium containing antacids is more popular among the consumers
than the H2 antagonists or proton pump inhibitors. Calcium car-
bonate tablets or supplements are widely consumed by patients
with osteoporosis or bone-related disorders for therapeutic pur-
pose. Similar is the case with intake of calcium-rich foods like milkrights reserved. This is an open access article under the CC BY-NC-ND license
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Anemia is another side effect with the sustained use of CPFX and
the preventive measure goes to prescribing MVs. Sometimes,
secondary disease conditions also necessitate the rational use of
MVs along with CPFX. MVs affect the bioavailability of the drug,
leading to further research to make it evidence based [2–8]. In-
dians are mainly lacto-vegetarian and use milk as a culturally ac-
ceptable measure for various conditions of GI tract disorders and
anemia.
The current research work aims at detecting the quantitative
effect of calcium (Ca), MVs and milk on the elimination of single-
dose CPFX in the urine of human volunteers by UV and HPLC.
Further research will be extended to see CPFX interactions with Ca,
milk and MVs by in vitro dissolution studies and establish in vitro–
in vivo correlation (IVIVC) which is a predictive mathematical
treatment describing the relationship between an in vitro property
of a dosage form (e.g. extent of drug release) and a relevant in vivo
response (e.g. amount of drug absorbed) [9–11]. In ciproﬂoxacin
assessment, urinary samples were preferred to blood samples
considering volunteer's compliance, convenient methodology,
concentration of drugs in the urine being higher than in the blood,
detection that can be made by simple analytical methods of UV,
lack of protein in the urine of a healthy volunteer obviating the
need for denaturation step, and no extra sample pretreatment (the
only caution is to look after urine dilutions) [12–16]. A novel ap-
plicational aspect of the current research was to establish IVIVC
using dissolution test as a surrogate for in vivo CPFX interactions
and bioavailability studies, which can waive the need for ex-
pensive human trials and hence is a suitable substitute for bioe-
quivalence studies [9–11,15,16].2. Materials and methods
2.1. Chemicals and reagents
All solvents used were of HPLC grade and reagents were of
analytical grade. HPLC grade water was used. Reagents as speciﬁed
like phosphoric acid, triethylamine and acetonitrile were pur-
chased from Merck and Sigma (Mumbai, India). CPFX was a gift
sample from M/s East India Pharmaceuticals Ltd., Kolkata and
Lomeﬂoxacin (internal standard, IS) from Macleods (Mumbai, In-
dia). CPFX ﬁlm coated tablets (500 mg), calcium tablets (500 mg)
and multivitamin syrup (Polybion
s
) were purchased from the local
market. Packed fresh cow milk was obtained from local dairy. Each
5 mL of Polybion syrup contained vitamin B1, 2 mg; vitamin B2,
2.5 mg; vitamin B6, 0.75 mg; nicotinamide, 15 mg; pantothenyl
alcohol, 3 mg; and vitamin-B12, 2 mg. The syrup speciﬁcation of
MV content was 16.03 for 100 mL, 34.28 for 250 mL, and 52.27 for
400 mL.
2.2. Instrumentation
UV spectrophotometric determinations were done in Thermo
Scientiﬁc (Mumbai, India). HPLC analyses were carried out in
Shimadzu LC 10 ADVp (Japan) with UV detector, and dissolution
studies were performed using USP Type ІІ dissolution test appa-
ratus (Labindia DS 8000, Mumbai, India).
2.3. Volunteer selection and urine collection
The study protocol followed the ethical principles for bio-
medical research involving human volunteers (ICMR 2009). Heal-
thy adult human volunteers (four males and females each) of 25–
35 years were selected (lottery) from a pool of 25 volunteers re-
siding locally with the body weight of 65–78 kg. Study time waswinter season. Volunteers were clinically assessed by physicians of
School of Medical Science and Technology, IIT Kharagpur. An-
thropometric status, blood biochemistry and hematology values
were within the normal limits in all these subjects. Smokers,
alcoholics, those with enzyme deﬁciencies, particularly renal and
hepatic insufﬁciencies, children, pregnant and lactating women,
non-cooperative and inconsistent individuals were excluded from
the study. Written consents of eight volunteers were obtained
after explaining them the research protocol in vernacular. The
volunteers were asked to maintain standard dietary conditions
(avoiding high caloric and junk food), deﬁnite water (1 L) intake,
normal physical activities, and avoidance of strenuous exercises
and work overloads in the ensuing days of study.
The volunteers were given one CPFX tablet (500 mg) on the
ﬁrst day; one CPFX tablet (500 mg) and vitamin B-complex
(Polybion, 15 mL) on the third day (out of four days of trial, a gap of
one day was kept between each day of trial so as to ensure com-
plete renal clearance of CPFX); one CPFX tablet (500 mg) and
calcium tablet (Calbon 500, Saga Lab; calcium carbonate 1.25 g) on
the ﬁfth day; and one CPFX tablet (500 mg) and 250 mL of cow-
milk immediately after tablet intake on the seventh day and no
other food or drink was ingested for the next 6 h on the seventh
day. Midstream urine samples of the eight volunteers were col-
lected in sterilized vials properly labeled on four days of drug in-
take maintaining the same time intervals (2, 4, 8, 12, and 16 h),
stored in refrigerator and protected from light.
In order to get reproducible urinary excretion studies, water
loading was done by ingesting 400 mL of water to the volunteers
after overnight fasting prior to the trial to promote diuresis and
enable collection of sufﬁcient urine samples [12]. Before drug
administration, the volunteers were instructed to ensure complete
urination; 1 h after water loading, the urine sample collected at
this time was taken as the blank sample. The volunteers were
instructed to take CPFX with 200 mL of water, followed by another
200 mL given at hour intervals for the next 4 h. The same proce-
dures were used for the four days of drug intake of trials and the
volunteers were instructed for complete emptying of the bladders
to collect sufﬁcient urine samples [12,15].
2.4. UV spectrophotometric analysis of urine samples
The UV analysis of the urine samples collected from the vo-
lunteers at different time intervals was carried out in the following
manner. Urine samples (0.4 mL) collected at different time inter-
vals were diluted with 20 mL of methanol: water (80:20, v/v). The
samples were scanned using the same diluents (methanol: water,
80:20, v/v) as blank and the wavelength range was ﬁxed between
200 and 400 nm [16–21].
For the quantitative estimation of CPFX release under different
study conditions, 0.4 mL of urine was diluted to 20 mL. The vo-
lume of urine collected in each case was 50 mL. UV absorbance
values of 0.4 mL of diluted urine samples at different time inter-
vals (2, 4, 8, 12, and 16 h) were plotted in the standard calibration
curve of CPFX and intrapolated to get the corresponding con-
centration of CPFX. Thus, the amount of CPFX present in 50 mL of
urine samples was calculated by unitary method.
2.5. HPLC analysis of the urine samples
HPLC analysis was carried out using inertsil ODS C18 column,
(150mm4.6mm, 5 mm) maintaining a column temperature of
20 °C, injection volume of 10 mL with a ﬂow rate of 1.2 mL/min,
and a run time of 10 min. The UV detector was set at a wavelength
of 278 nm.
A 7 mL of triethylamine was diluted in 1000 mL of HPLC grade
water and then adjusted to a pH of 3.0 with phosphoric acid, well
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degassed mixture of 0.025 M H3PO4 (adjusted to a pH of 3.0 with
triethylamine) and acetonitrile in the ratio of 87:13 (v/v).
In HPLC studies, quantitative estimation of CPFX release under
different study conditions was determined according to the fol-
lowing equation:
A W D P A
A W D
% assay 100t s t w
S t s
= × × × ×
× ×
×
where At is the average area of major peak in test chromatogram,
As is the average area of major peak in standard CPFX chromato-
gram,Wt is the wt of test taken in mg (to get from HPLC calibration
curve),Ws is the wt of std CPFX taken in mg (11/30/60 mg), P is the
purity of working standard (99.5%), Dt is the dilution of test
samples (50 times diluted), Ds is the dilution of standard solution,
and Aw is the average wt of tablet (500 mg).
2.6. Dissolution studies
Absorption and hence bioavailability of the drug greatly de-
pend on the dissolved state of the drug. Therefore, dissolution rate
is a critical step in the performance of a drug and its dosage forms.
This step of a drug is found to be affected by co-administered
drugs and other food ingredients [9,10,14,22–26].
In vitro CPFX interaction with calcium, MVs and milk was stu-
died in USP Type ІІ dissolution test apparatus with certain mod-
iﬁcations of the reported literature [24,27–31]. Brieﬂy, dissolution
study of CPFX tablets was carried out in 500 mL of dissolution
media under simulated gastric and intestinal pH conditions (pH
1.2 and 6.8, respectively), thermostated at 3775 °C and operated
at 100 rpm. 5 mL of aliquots of dissolution media were withdrawn
at predetermined time intervals (5, 15, 30, 45, 60, 90 and 120 min)
and their absorbance was measured at 276 nm in UV
spectrophotometer.
For testing the action of calcium on the dissolution behavior of
CPFX, calcium tablet was added to the dissolution mediumwith an
appropriate concentration of CPFX at the start of the experiment
while other conditions remained the same. Aliquots of the dis-
solution medium were withdrawn and CPFX concentrations were
determined spectrophotometrically at 276 nm.
In vitro milk–CPFX interaction studies were conducted in
500 mL of dissolution media, and other conditions remained the
same as above. One FDA glass (250 mL) of low fat milk was added
to the dissolution media with an appropriate concentration of
CPFX at the start of the experiment; CPFX concentrations were
determined spectrophotometrically at 276 nm.
In vitro MVs–CPFX interaction studies were conducted in
500 mL of dissolution media, and other conditions remained as
before. A 55 mL of Polybion syrup was added to the dissolution
media with an appropriate concentration of CPFX at the start of
the experiment; CPFX concentrations were determined spectro-
photometrically at 276 nm. In all the above in vitro dissolution
studies, the aliquots withdrawn were not replenished with fresh
equivalent amount of dissolution media.
Cumulative percentage of CPFX release proﬁles was character-
ized by the area under the dissolution curves (AUC) up to a time ‘t’
in simulated gastric and intestinal ﬂuids (SGF and SIF) under dif-
ferent study conditions. The AUC for each dissolution proﬁle was
calculated by the trapezoidal rule [32–34].
2.7. Comparison of dissolution data
The dissolution proﬁles were further analyzed by difference
factor (f1) and similarity factor (f2). Difference factor (f1) is the
percentage difference between two curves at each point and is ameasurement of the relative error between the two curves. The
similarity factor (f2) is a logarithmic reciprocal square root trans-
formation of the sum of squared error and is a measurement of the
similarity in the percent dissolution between the two curves [35–
37]. The following equations were used to calculate f1 and f2 va-
lues:
⎡⎣ ⎤⎦f n R T R1 / 100t t t t n t1 1{ }[ ]Σ Σ= | – | ×= =
f X n R T2 50 log 1 1/ 100t
n
t t1
2 0.5Σ= {[ + ( ) ( – ) ] × }= −
where n is the number of points, Rt is the dissolution value of the
reference product at time t, and Tt is the dissolution value for the
test product at time t. For dissolution curves to be considered si-
milar, f1 should be close to zero and f2 should be close to 100.
Generally, f1 value ranges up to 15 (0–15) and f2 values are greater
than 50 (50–100), which ensures equivalence between the two
curves.
In this research, CPFX was used as the standard substance and
CPFXþCa, CPFXþMVs and CPFXþmilk were used as the reference
substances. Comparison was made for both in vitro SIF and SGF
conditions using f2 values. The more the deviation from the
standard value, the greater the accuracy of the experimental
methodology.
2.8. IVIVC studies
IVIVC is a predictive mathematical treatment describing the
relationship between in vitro properties of a dosage form (e.g.
extent of drug release) and a relevant in vivo response (plasma
drug concentration or amount of drug absorbed). IVIVC has drawn
the attention and is worthy of consideration by pharmaceutical
industries, academics and regulatory sectors. If in vitro tests can
suitably reﬂect bioavailability data, it is helpful to waive bioequi-
valence studies on healthy volunteers. Among the three main le-
vels (A, B and C) of IVIVC, level A (the highest grade) relates the
entire in vitro dissolution curve to in vivo concentration proﬁle
(in vivo absorption curve) so that in vitro dissolution can serve as a
surrogate marker for in vivo drug actions study; level B of IVIVC
utilizes Statistical Moments Analysis to compare the mean of any
parameter of in vitro dissolution (e.g.mean dissolution time, MDTin
vitro) with the mean of any in vivo parameter (e.g. mean residence
time, MRTin vivo); level C of IVIVC establishes a single point cor-
relation between an in vitro dissolution parameter (e.g. time to
release 50% or 90% of the active drug, T50% or T90%) and corre-
sponding in vivo parameter (e.g. Cmax, Tmax or AUC) [9–11,32,38–
41].
In this study, IVIVC was determined by plotting the percentage
of CPFX released (CPFXrel) in vitro (from dissolution studies)
against the cumulative percentage of CPFX excreted in urine for a
sufﬁcient period of time which is directly related to the total
amount of CPFX absorbed.3. Results
The mean (7SD) values of various parameters of the eight
volunteers were determined as follows: age, 27.374.16 years;
weight, 69.578.01 kg; height, 170.376.45 cm; body surface area
(BSA), 1.776.95 m2; systolic blood pressure, 12370.82mmHg;
and diastolic blood pressure, 8070.91 mmHg. Linearity details of
the standard calibration curves of CPFX for UV, HPLC and dis-
solution studies are presented in Table 1. The quantitative elim-
ination of CPFX at hourly intervals (2, 4, 8, 12, and 16 h) was de-
termined from the standard calibration curve of UV and HPLC
studies and is shown in Figs. 1–3. The peak areas (7SD) values of
B. Dey et al. / Journal of Pharmaceutical Analysis 5 (2015) 389–395392CPFX eliminated at hourly intervals in the urine of eight volunteers
as detected in HPLC analysis are provided in Table 2. The phar-
macokinetic parameters determined from the urinary excretion
data obtained from UV and HPLC studies are summarized inTable 1
Data of calibration curve of CPFX for UV, HPLC and dissolution studies.
Parameters UV studies HPLC studies Dissolution studies
95% conﬁdence intervals
Slope 0.105–0.108 12.82–13.78 0.141–0.163
Y-intercept 0.0013–0.0109 11.84–22.54 0.0406–0.0468
X-intercept 0.103–0.0125 1.748–0.864 0.330–0.250
Goodness of ﬁt
R2 0.999 0.999 0.997
P value o0.0001 o0.0001 o0.0001
Equation Y¼0.1072Xþ0.004 Y¼13.30Xþ5.348 Y¼0.1522Xþ0.003
Best ﬁt values
Slope (7SD) 0.107270.0004 13.3070.18 0.152270.004
Y-intercept
(7SD)
0.00478570.002 5.34876.68 0.00313370.015
X-intercept 0.0446 0.402 0.0205
Fig. 1. Quantitative elimination of CPFX at hourly intervals under different study
conditions (UV studies).
Fig. 2. Quantitative elimination of CPFX at hourly intervals under different study
conditions (HPLC studies).Tables 3 and 4. The in vitro cumulative CPFX elimination in SGF and
SIF under different study conditions is shown in Tables 5 and 6 and
Suppl. Figs. 1 and 2. Comparisons of dissolution proﬁles under
different study conditions both in SGF and SIF were made based onFig. 3. Cumulative elimination of CPFX under different study conditions (HPLC
studies).
Table 2
Peak area values of CPFX eliminated in the urine of the 8 volunteers in HPLC studies
under different conditions.
Time (h) CPFX alone CPFXþMVs CPFXþcalcium CPFXþmilk
2 34117185 31847187 18937153 24307157
4 20277210 59907300 30737262 33727190
8 13747391 1254795 13827310 17467146
12 8577299 9237177 10097154 9547187
CPFX, ciproﬂoxacin; MVs, multivitamins.
Table 3
Pharmacokinetic parameters of urinary excretion data by UV.
Pharmacokinetic
parameters
CPFX (alone) CPFXþMVs CPFXþCa CPFXþmilk
AUC0 t (μg/mL h) 8903.92 10,238.64 9490.73 9742.78
AUC0α (μg/mL h) 11,702.83 13,121.11 12,237.17 12,196.97
t1/2 (h) 3.203 3.101 3.118 3.067
ka (1/h) 0.2440 0.2568 0.2529 0.2768
Cl/F (mg)/((μg/mL)/h) 0.04272 0.03810 0.04085 0.04099
Cmax (μg/mL) 988.21 1154.62 1065.87 1118.50
Tmax (h) 4.348 4.170 4.214 3.991
AUMC (μg/mL h2) 102,029.75 109,795.28 103,441.46 98,026.88
MRT (h) 8.718 8.367 8.453 8.037
Table 4
Pharmacokinetic parameters of urinary excretion data by HPLC.
Pharmacokinetic values CPFX (alone) CPFXþMVs CPFXþCa CPFXþmilk
AUC0–t (μg/mL h) 924.87 1897.50 1527.87 1515.68
AUC0–α (μg/mL h) 1531.31 7204.61 2342.38 1515.68
t1/2 (h) 4.212 26.584 4.245 0.327
ka (1/h) 0.175 3.632 0.214 4.235
Cl/F (mg)/((μg/mL)/h) 0.3265 0.0694 0.2134 0.3298
Cmax (μg/mL) 95.64 181.26 160.12 1603.94
Tmax (h) 5.887 1.368 5.332 0.327
AUMC (μg/mL h2) 18,042.98 278,306.31 25,287.54 1074.26
MRT (h) 11.782 38.628 10.795 0.709
Table 5
In vitro data of CPFX release in SGF (dissolution studies).
Time (min) CPFXa CPFXþCab CPFXþmilk CPFXþMVsc
0 0 0 0 0
5 26.80 8.14 5.7 8.1
15 38.20 36.54 12.8 10.9
30 50.45 40.91 15.4 16.7
45 66.50 42.15 16.9 22.9
60 70.23 42.91 25.3 29.4
90 82.45 45.01 28.1 32.1
120 98.01 47.24 30.9 35.5
a CPFX, ciproﬂoxacin.
b Ca, calcium.
c MVs, multivitamins.
Table 6
In vitro data of CPFX release in SIF (dissolution studies).
Time (min) CPFXa CPFXþCab CPFXþ milk CPFXþMVsc
0 0 0 0 0
5 27.1 10.6 6.2 5.9
15 43.5 25.3 11.1 10.7
30 57.8 32.4 12.7 18.1
45 73.5 39.0 16.7 24.2
60 80.1 45.2 22.8 28.0
90 92.7 47.4 31.5 34.5
120 99.0 49.5 36.2 38.9
a CPFX, ciproﬂoxacin.
b Ca, calcium.
c MVs, multivitamins.
Table 7
Correlation coefﬁcient (R2) values obtained from IVIVC data of CPFX release under
different conditions.
Media CPFXa CPFXþMVsb CPFXþCac CPFXþmilk
UV method
SGF–urine 0.999 0.918 0.664 0.908
SIF–urine 0.997 0.953 0.786 0.974
HPLC method
SGF–urine 0.984 0.860 0.651 0.899
SIF–urine 0.995 0.924 0.801 0.951
a CPFX, ciproﬂoxacin.
b MVs, multivitamins.
c Ca, calcium.
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(CPFXþmilk) and 31.31 (CPFXþMVs), and in SIF they were found
to be 36.36 (CPFXþCa), 31.2 (CPFXþmilk) and 32.16 (CPFXþMVs).
For IVIVIC studies, the correlation coefﬁcient of CPFX release both
in vitro (dissolution studies) and in vivo (urinary excretion studies)
are presented in Table 7 and Suppl. Figs. 3–6.4. Discussion
Our research data showed that elimination of CPFX (either
cumulative release or at hourly intervals) increased signiﬁcantly
when co-administered with MVs, Ca-tablets and milk as evident
by in vivo UV and HPLC urinary excretion studies and in vitro
dissolution studies. Elimination of CPFX was markedly increased in
the order of MVs4milk4calcium in contrast to CPFX release
when administered alone.Analyses of pharmacokinetic parameters showed that an in-
crease in ka values increased the Cmax and vice versa. In contrast,
Tmax values were found longer with smaller ka values and shorter
with larger ka values. However, ka values did not show any inﬂu-
ence on the AUC.
The similarity factor, f2 values, ranged from 29.77 to 36.36,
suggesting the accuracy of our in vitro experimental methodology
[35–37]. From the point of IVIVC studies, our research data showed
R2 values ranging from 0.651 to 0.999 under different study con-
ditions, thus exhibiting a good correlation. Estimation of CPFX
elimination under different conditions and determination of the
IVIVC based on urinary excretion data were found to be simple,
reliable and cost-effective. The simultaneous dissolution studies
could serve as a bio-waiver for expensive human trials and hence
this method could be a suitable substitute for bioequivalence
studies. Dissolution studies can serve as a surrogate for in vivo
bioavailability and support bio-waivers.
Prolonged antibiotic therapy causes anemia, gastric irritation or
acidity; thus, antacids and multi-vitamin formulations are the
commonly co-administered drugs with antibiotics [1,5,8]. Calcium
either in the form of carbonate or chloride is a constituent of many
marketed antacid formulations [2,3,42,43]. Multivitamin for-
mulations, especially with mineral contents, are found to reduce
the bioavailability of ﬂuoroquinolones [4,5,8]. It is a common
practice of many patients to intake drugs with drinks like milk,
yogurt or juices other than water. Moreover, calcium-enriched
foods and dairy products are often included in the breakfast menu
of patients undergoing treatment [6,7,24]. Our research ﬁndings
showed that the bioavailability of CPFX was signiﬁcantly reduced
by co-administration of MVs followed by that of milk and calcium.
Calcium or its salts chelates or binds with CPFX, preventing its
absorption and thereby reducing its bioavailability. However, milk
was found to inhibit absorption of CPFX more than calcium alone
mostly because of CPFX interactions with the milk matrix which
decreased CPFX absorption by complexation with metal ions pre-
sent in milk and by adsorption at the surface of milk protein
molecules mostly casein (forms 84% of total milk protein), thus
providing additional inhibitory effect and preventing absorption of
CPFX [24]. Structurally, each CPFX molecule has one RCOOH
group which readily interacts with Ca2þ ions (also other poly ca-
tions) [41]. The R–COOH group of CPFX becomes negatively
charged, releasing Hþ ion, determined by its pKa value. The pKa for
carboxyl groups ranges between 1.8 and 2.4 [12,13]. Thus, a pH
above this pKa would result in a greater percentage of the carboxyl
groups on CPFX being ionized. Depending on other mechanisms
like intake of antacids containing metals like calcium, H2 antago-
nists, proton pump inhibitors; the type of food ingested by the
patient; and the pH of the stomach which mostly ranges from 1 to
6, it is likely that the pKa of the carboxyl group will be exceeded
[13,41]. However, if the patient takes only CaCO3 containing for-
mulations with CPFX on an empty stomach, CaCO3 can interact
with gastric HCl to form CaCl2, CO2 and H2O, thus increasing the
gastric pH value. Therefore, the magnitude of change in gastric pH,
whether it is from CaCO3 itself or from combination of CaCO3 and
other medications, can inﬂuence the amount of ionized carboxyl
groups found on CPFX. Owing to such ionization, the exposed and
negatively charged groups on CPFX bind with the positively
charged Ca2þ ions that are present in the medication or supple-
ment administered, referred to as chelation. The degree or sig-
niﬁcance of this interaction is, however, dependent on the time of
exposure to one another and the pH of the environment at that
time [2,13,24,26,41–44]. A 2 h separation of the calcium containing
products and the CPFX can avoid this interaction. The same logic
can be applied for MVs necessitating a gap of about 4 h between
CPFX and intake of MV. If the co-administration of other drugs or
food ingested decreases absorption or bioavailability of CPFX, it
B. Dey et al. / Journal of Pharmaceutical Analysis 5 (2015) 389–395394potentially increases the risk of infection treatment failure and a
drug producing sub-therapeutic actions for a long time leads to
development of antimicrobial resistance against that particular
antibiotic. Thus, the potency of a renowned antibiotic becomes
greatly hindered due to drug–drug and drug–food interactions.5. Conclusions
Drug–food and drug–drug interactions are matters of concern
since the therapeutic efﬁcacy and bioavailability of renowned
drugs get greatly suppressed. Moreover, severe adverse drug re-
actions may also be precipitated. Our current research showed a
signiﬁcant reduction in the bioavailability of popular antibiotic
CPFX on interactions with MVs, calcium tablets and milk. Thus, to
prevent sub-therapeutic effects and protect against development
of anti-microbial resistance, patients should consider taking CPFX
and other Ca-containing medicaments at a lag period of 2 h and
above. The same solution can be applicable to other dairy and
milk products. For MVs, a lag period of at least 4 h is
recommended.
The UV-HPLC analytical methodology followed the estimation
of CPFX elimination under different study conditions was found to
be simple, reliable and cost-effective. Determination of IVIVC
based on urinary excretion data showed that dissolution studies
can serve as a bio-waiver for expensive human trials and hence
the developed methods can be suitable substitutes for bioequiva-
lence studies.Acknowledgments
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